Brief: Pepgen Announces Positive Data From Ongoing Phase 2 Trial For Treatment Of Duchenne Muscular Dystrophy

PepGen

30/07/2024 21:22

July 30 (Reuters) - PepGen Inc  PEPG.O :
    * PEPGEN ANNOUNCES POSITIVE DATA FROM LOW-DOSE COHORT OF
PGN-EDO51
IN ONGOING CONNECT1-EDO51 PHASE 2 CLINICAL TRIAL FOR TREATMENT
OF DUCHENNE MUSCULAR DYSTROPHY
    * PGN-EDO51 AT 5 MG/KG WAS WELL TOLERATED
    * PGN-EDO51 AT 5 MG/KG SHOWED MEAN MUSCLE-ADJUSTED
DYSTROPHIN
LEVEL OF 1.49%, A 0.70% INCREASE FROM BASELINE, AFTER THREE
MONTHS OF DOSING
    * PGN-EDO51 AT 5 MG/KG SHOWED MEAN ABSOLUTE DYSTROPHIN LEVEL
OF
0.61%, A 0.26% INCREASE FROM BASELINE, AFTER THREE MONTHS OF
DOSING

Source text for Eikon:  ID:nBw4Hv6Bha 
Further company coverage:  PEPG.O 

 ((Reuters.Briefs@thomsonreuters.com;))